- Previous Close
16.23 - Open
16.25 - Bid 16.50 x 100
- Ask 16.65 x 200
- Day's Range
16.25 - 16.90 - 52 Week Range
5.63 - 26.35 - Volume
775,665 - Avg. Volume
356,777 - Market Cap (intraday)
1.494B - Beta (5Y Monthly) 0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-2.62 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.00
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
www.newamsterdampharma.comRecent News: NAMS
View More
Performance Overview: NAMS
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NAMS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NAMS
View MoreValuation Measures
Market Cap
1.49B
Enterprise Value
1.06B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
194.63
Price/Book (mrq)
3.86
Enterprise Value/Revenue
143.33
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.15%
Return on Equity (ttm)
-54.08%
Revenue (ttm)
7.42M
Net Income Avi to Common (ttm)
-229.4M
Diluted EPS (ttm)
-2.62
Balance Sheet and Cash Flow
Total Cash (mrq)
430.71M
Total Debt/Equity (mrq)
0.14%
Levered Free Cash Flow (ttm)
-108.42M
Research Analysis: NAMS
View MoreCompany Insights: NAMS
NAMS does not have Company Insights